Below is the latest Dana email newsletter. You can sign up to receive this (and other Dana email alerts and/or print publications) by going here.
by Steven E. Hyman, M.D.
When it comes to funding drug research to treat depression, schizophrenia, anxiety, and other psychiatric disorders, the global pharmaceutical industry prefers to invest its research dollars in cancer, metabolism, autoimmunity, and other disease areas. This comes despite the fact that one in five Americans currently take at least one psychiatric drug and that mental disorders are recognized worldwide. The author traces the evolution of psychiatric drug development, the reasons for its retreat, and what needs to change to meet the growing demand. From Cerebrum, our online magazine of ideas.
Amidst an explosion of oxytocin research, neuroscientists express cautious enthusiasm about the hormone's potential applications, but also warn of misperceptions brought on by oversimplified reporting.